Drug makers who aim to co-develop two drugs in therapeutic combinations face a burden of putting together more than twice the preclinical data needed to pave a single drug’s way to the clinic because of the complexity of dosing the two drugs effectively, panelists agreed at the American Association for Cancer Research April 3.
The panel on co-development of investigational drugs was part of a new Regulatory Science and Policy Track added to the AACR program in keeping with the meeting’s translational “concept to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?